Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A synthetic small molecule belonging to the isosorbide class of organic compounds. It features two amidinophenyl groups attached to a dianhydro derivative of D-sorbitol. The compound has been referenced as a small molecule drug in chemical and biological databases but lacks evidence of clinical use or approval. Its mechanism of action is not well characterized in the literature; however it has been associated with interaction studies involving serine protease targets such as PRSS1 (trypsinogen). There are no known approved indications or marketed products containing this compound[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 2,5-O,O-bis-{4',4''-amidinophenyl}-1,4:3,6-dianhydro-D-sorbitol.